Diasmoke

A Randomized Controlled Multicentre Study evaluating changes in Cardiovascular Risk Factors in Smokers with type 2 Diabetes Mellitus after switching from Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE 2.0 Study

Smoking and diabetes

Living with diabetes means facing the choice of a healthy lifestyle every day. Having diabetes means having a disease that often raises blood sugar levels in a worrying way. There are several types of diabetes. Type 2 is the most common in adults and accounts for over 90% of all diabetes cases. Fewer people have type 1 diabetes, which more often develops in children, adolescents, or young adults.

Smoking and diabetes are a bad combination. Regardless of the type of diabetes you have, smoking makes your diabetes harder to control. If you have diabetes and smoke, you are more likely to have serious diabetes-related health problems. Smokers with diabetes have a higher risk of serious complications.

What is Diasmoke

Little is known about the impact of combustion-free nicotine delivery sistem on type 2 diabetes mellitus (T2DM) patients who smoke. DIASMOKE (Assessing the impact of combustion free-nicotine delivery technologies in Diabetic Smokers) is an international, multicenter, open label randomized controlled study designed to determine wheter T2DM cigarette smokers switching to CF-NDS experience measurable improvement in cardiovascular risk parameters as a consequence of avoiding exposure to cigarette smoke toxicants.

This study aims to test the hypothesis that avoiding exposure to cigarette smoke toxicants may translate to measurable improvement in cardiovascular risk factors and functional parameters when T2DM patients who smoke switch to using C-F NDS compared with T2DM patients who continue to smoke conventional tobacco products.

Your health will be monitored and monitored continuously.

What Does the Study Involve?

The study involves recruiting a total 576 patients will be randomized to either a control arm, in which they will be offered referral to smoking cessation programs or to an intervention arm, in which they will be assigned to C-F NDS use.

What is the Aim of Diasmoke?

Aim of Diasmoke is to determine whether type 2 diabetes mellitus cigarettes smokers whose switch to combustion free nicotine delivery system experience measurable improvements in cardiovascular risk parameters

Why participate in Diasmoke

Monitoring and medical supervision than would usually be available through standard NHS care and important research support for diabetes prevention and treatment. Each participant will be offered access to local free smoking cessation programs.

What is the purpose of the study?

This study investigates whether vaping or using E-cigarettes reduces the risk of cardiovascular (heart and circulation) disease as compared to normal smoking. The results of the study may help us to understand more about the risks of vaping or e-cigarettes and normal cigarettes for diabetes patients who are smokers.

What do we ask you?

Before randomization, all smokers will be reminded of the risks associated with smoking and will be offered a free smoking cessation program according to standard local guidelines and depending on the local availability of antismoking services. Everyone who joins the study will be randomly chosen to be in one of two groups of participants. One group will be asked to carry on smoking their usual cigarettes for the duration of the study, and the second group will be asked to switch to vaping.

Duration

The study will last approximately 2 years in total. After the basic checkup, you will be asked to come back for another four checkups after 3 months, 6 months, one year and two years.

DiasmokeFree Working Group

In 2023, the Diasmoke research team set up an International Working Group with the world’s leading experts in diabetes to address the issue of smoking harm in people with diabetes, in its clinical, medical, behavioral and sociological implications, in order to provide independent consultation and oversight to the development of smoking cessation / harm reduction guidelines for smokers with type 2 diabetes mellitus.

Group Coordinator

Riccardo Polosa

Center of Excellence for the Acceleration of HArm Reduction [CoEHAR], University of Catania, Catania, Italy; Centre for the Prevention and Treatment of Tobacco Addiction [CPCT], Catania, Italy; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

Group Members

Davide Campagna

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

Agostino Di Ciaula

Clinica Medica “A. Murri,” Department of Precision and Regenerative Medicine and Ionian Area [DiMePre-J], University “Aldo Moro” Medical School, Bari, Italy

Tabinda Dugal

Royal Cornwall Hospital NHS Trust, Treliske, Truro, U.K.

Andre Kengne

Non-Communicable Diseases Research Unit, South African Medical Research Council and University of Cape Town, Cape Town, South Africa; Department of Biological and Environmental Science, Faculty of Science, Walter Sisulu University, Mthatha, South Africa

Anoop Misra

Diabetes Foundation [India], New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation [N-DOC], New Delhi, India; Fortis C-DOC Centre for Excellence for Diabetes, Metabolic Disease, and Endocrinology, New Delhi, India

Syed Abbas Raza

Shaukat Khanum Cancer Hospital and Research Center, Peshawar, Pakistan

Cristina Russo

Ashford and Saint Peter’s Hospitals NHS Foundation Trust, Chertsey, U.K.

Roberta Sammut

Faculty of Health Sciences, University of Malta, Valletta, Malta; id-Dar tal-Providenza, Siggiewi, Malta

Noel Somasundaram

Diabetes and Hormone Center, Colombo, Sri Lanka; South Asian Federation of Endocrine Societies, Colombo, Sri Lanka; National Hospital of Sri Lanka, Colombo, Sri Lanka; Endocrine Society of Sri Lanka, Colombo, Sri Lanka

Magdalena Walicka

Department of Human Epigenetics, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; Department of Internal Diseases, Endocrinology, and Diabetology, The National Institute of Medicine of the Ministry of Interior and Administration, Warsaw, Poland

The group published a letter in Diabetes Care, to suggest to the American Diabetes Association a correction of the ADA guidelines regarding the use of e-cigarettes among patients with diabetes.

Comment on Elsayed et al. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl. 1):S68–S96

Press

DiaSmoke Free Working Group Challenges American Diabetes Association Guidelines on E-Cigarette Use

30 October 2023

Diasmoke Working Group in Warsaw: how to address the smoking issue among diabetes patients?

28 June 2023

At GFN 2023, SAB Diasmoke second meeting

20 June 2023

Diabetes and smoking: international meeting on the development of new guidelines in Catania

3 April 2023

Diasmoke 2.0: how to participate to the project?

28 October 2022

First study in the world to evaluate efficacy and safety of the antismoking drug varenicline for smokers with Diabetes

21 June 2022

CoEHAR is the promoter and coordinator
of the Diasmoke Study

CoEHAR is a unique multidisciplinary research center focused on the study of Tobacco Harm Reduction. Innovation, peer-review research, and globalization of ideas are at the core of CoEHAR actions.

Established in 2018 at the University of Catania, CoEHAR has a large network of international collaborations with experts from different fields and countries. CoEHAR mission is to create a new global, shared and controlled science that can improve its applications with specific solutions for the needs of each country and territory.